Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway...
Hence then, the article about calcimedica announces private placement financing for up to approximately 49 million to advance pulmonary hypertension program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program )
Also on site :
- Congress passes war powers measure for first time, rebuking Trump's war with Iran
- Olympic gold medalist Haley Winn visits Plank Road South Elementary in Webster
- Best Prime Day 2026 Tech Deals Under $100: Save Up to 75% on Bose, Beats by Dre, Samsung & Other Top Brands